期刊文献+

负载紫杉醇的双配体纳米药物输送系统的制备 被引量:3

Preparation and Characterization Heparin-based Nanoparticle with Dual Ligands to Deliver Paclitaxel
下载PDF
导出
摘要 目的:带有叶酸和穿膜肽双配体的、负载紫杉醇纳米药物输送系统的制备及其表征。方法:以丁二酰化肝素为原料,利用碳二亚胺法偶联叶酸和穿膜肽,制备肝素-叶酸-穿膜肽偶联物,然后将紫杉醇包裹在肝素-叶酸-穿膜肽载体中,在水溶性条件下自组装成肝素-叶酸-穿膜肽-紫杉醇纳米粒子。本研究采用核磁共振氢谱(1H NMR),动态光散射(DLS)和透射电子显微镜(TEM)对自组装的纳米粒子进行表征,观测其在水溶性条件下的自组装行为。结果:成功构建了肝素-叶酸-穿膜肽-紫杉醇纳米粒子,检测表明纳米粒子含有8.5%的叶酸和5.5%穿膜肽并负载8.3%紫杉醇(w/w),TEM和DLS检测表明形成了不规则的球形纳米颗粒,粒径为78nm左右。结论:我们成功制备了带有双配体的负载紫杉醇的纳米药物输送系统,在进一步开展的生物活性的检测中,希望通过叶酸受体的靶向作用和穿膜肽穿膜作用,提高药物在靶细胞的聚集,进一步增强药物输送系统的治疗作用,为开发新型、高效药物输送系统提供基础。 Objective.. Preparation and characterization of heparin-based nanoparticles delivery of paclitax- el composed of folate and Tat dual ligands. Methods: Succinyl-heparin was used to conjugate with folate and Tat by EDC/NHS, and then paclitaxel was entrapped into heparin-folate-Tat carrier and formed a self-assem- bled heparin-folate-Tat-paclitaxel nanoparticle in aqueous solution. The naoparticles was characterized by 1H NMR, transmission electron microscopy (TEM) and dynamic lighting scatter (DLS), respectively. Results. The heparin-folate-Tat-paclitaxel nanoparticles were successfully prepared. The weight percentage of folate, Tat and paclitaxel was about 8. 5 ~, 5.5 and 8. 4 %, respectively. The morphology of nanoparticles was ap- proximately spherical shape as measured by TEM and the size of nanoparticles was about 78 nm as deter- mined by DLS. Conclusions. We fabricated heparin-based nanoparticles with dual ligands to deliver paclitaxel which promoted us to further investigate its biological activities. The strategy on nanomedicine with dual lig- ands was expected to enhance the cellular uptake of drug thereby improving promising its chemotherapeutic efficiency. The nanoparticle system could be used as a promising cancer cell specific delivery system for fur- ther investigation.
出处 《数理医药学杂志》 2013年第4期450-453,共4页 Journal of Mathematical Medicine
基金 国家自然科学基金(21204036) 广东省自然科学基金资助(S2011040003731)
关键词 叶酸 穿膜肽 紫杉醇 纳米药物输送系统 制备 folate tat paclitaxel nanoparticle system preparation
  • 相关文献

参考文献10

  • 1Steichen S D, Caldorera-Moore M, Peppas N A. A review of cur- rent nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci, 2012, 48(3) : 416-427.
  • 2RossJ F, Chaudhuri P K, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications . Cancer, 1994, 73 (9): 2432-2443.
  • 3Campbell I G, Jones T A, Foulkes W D, Trowsdale J. Folate- binding protein is a marker for ovarian cancer. Cancer Res, 1991, 51(19): 5329-5338.
  • 4Ak G, Sanlter S H. Synthesis of folate receptor-targeted and Doxorubicin-coupled chemotherapeutic nanoconjugate and research into its medical applications. Prep Biochem Biotechnol, 2012, 42 (6) : 551-563.
  • 5Dhawan D, Ramos-Vara J A, Naughton J F, et al. Targeting fo- late receptors to treat invasive urinary bladder cancer. Cancer Res, 2013, 73(2):875-884.
  • 6Wang Y, Newell B B, Irudayaraj J. Folic acid protected silver nanocarriers for targeted drug delivery . J Biomed Nanotechnol, 2012, 8(5): 751-759.
  • 7Dietz G P, Bahr M. Delivery of bioaetive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci, 2004, 27 (2): 85 -131.
  • 8Cheng C J, Saltzman W M. Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrat- ing peptides. Biomaterials, 2011, 32: 6194-6203.
  • 9Zhao P, Wang H, Yu M, et al. Paclitaxel-loaded, folic-acid-targe- ted and TAT-peptide-conjugated polymeric liposomes: in vitro and in vivo evaluation. Pharm Res, 2010, 27(9): 1914-1926.
  • 10Wang Y, Wang Y, Xiang J, et al. Target-specific cellular uptake of taxol-loaded heparin-PEG-folate nanoparticles . Biomacromolecules, 2010, 11(12) :3531-3538.

同被引文献44

  • 1Tran PH,Tran TT,Vo TV,et al.Novel multifunctional biocompati ble gelatin-oleic acid conjugate:self-assembled nanoparticles for drug delivery[J].J Biomed Nanotechnol,2013,9(8):1416-1431.
  • 2Augustin MA,Sanguansri L,Lockett T.Nano-and micro-encapsulated systems for enhancing the delivery of resveratrol[J].Ann NY Acad Sci,2013,1290:107-112.
  • 3Snehalatha M,Kolachina V,Saha RN,et al.Enhanced tumor uptake,biodistribution and pharmacokinetics of etoposide loaded nanoparticles in Dalton's lymphoma tumor bearing mice[J].J Pharm Bioallied Sci,2013,5(4):290-297.
  • 4Yang T,Sheng HH,Feng NP,et al.Preparation of andrographolideloaded solid lipid nanoparticles and their in vitro and in vivo evaluations:characteristics,release,absorption,transports,pharmacokinetics,and antihyperlipidemic activity[J].J Pharm Sci,2013,102(12):4414-4425.
  • 5Afifi MM,Austin LA,Mackey MA,et al.XAV939:from a small inhibitor to a potent drug bioconjugate when delivered by gold nanoparticles[J].Bioconjug Chem,2014,25(2):207-215.
  • 6Yuan F,Dellian M,Fukumura D,et al.Vascular permeability in a human tumor xenograft:molecular size dependence and cutoff size[J].Cancer Res,1995,55(17):3752-3756.
  • 7Duncan R,Sat-Klopsch YN,Burger AM,et al.Validation of tumour models for use in anticancer nanomedicine evaluation:the EPR effect and cathepsin B-mediated drug release rate[J].Cancer Chemother Pharmacol,2013,72(2):417-427.
  • 8Maeda H,Bharate GY,Daruwalla J.Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect[J].Eur J Pharm Biopharm,2009,71(3):409-419.
  • 9Endo K,Ueno T,Kondo S,et al.Tumor-targeted chemotherapy with the nanopolymer-based drug NC-6004 for oral squamous cell carcinoma[J].Cancer Sci,2013,104(3):369-374.
  • 10Zhao BJ,Ke XY,Huang Y,et al.The antiangiogenic efficacy of NGR-modified PEG-DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats[J].J Drug Target,2011,19(5):382-390.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部